Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Dulaglutide

Dulaglutide

GLP-1 · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 1 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Trulicity
Mechanism
GLP-1
Route
s.c.
Company
Eli Lilly
Highest development stage
—
Status (as of data cut)
Approved (T2D); not developed for obesity verify
Next milestone
—

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Cardiovascular and kidney outcome trials

REWIND dulaglutide 1.5 mg vs placebo · T2D, broad CV risk · n = 9901 · 2019 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of non-fatal MI, non-fatal stroke, or death from cardiovascular causes (including unknown causes)
0.880.79–0.99594 vs 663verified
Cardiovascular death
Cardiovascular death (includes deaths of unknown cause)
0.910.78–1.06317 vs 346verified
All-cause death
Death from any cause
0.900.80–1.01536 vs 592verified
Myocardial infarction
Myocardial infarction (fatal or non-fatal)
0.960.79–1.15223 vs 231verified
Stroke
Stroke (fatal or non-fatal)
0.760.62–0.94158 vs 205verified
Hospitalisation for heart failure
Hospital admission for heart failure or urgent visit requiring therapy
0.930.77–1.12213 vs 226verified
Kidney composite
Composite renal outcome: new macroalbuminuria (UACR >33.9 mg/mmol), sustained eGFR decline of 30% or more from baseline, or chronic renal replacement therapy
0.850.77–0.93848 vs 970verified
Retinopathy complications
Eye outcome (clinical diabetic retinopathy): photocoagulation, anti-vascular endothelial growth factor therapy, or vitrectomy (component of the composite microvascular outcome)
1.240.92–1.6895 vs 76verified
Hospitalisation for unstable angina
Hospital admission for unstable angina
1.140.84–1.5488 vs 77verified
Verbatim quotes (9)
  • 3-point MACE · Results, paragraph 3; Table 2
    the primary composite outcome occurred in 594 (12·0%) participants ... assigned to dulaglutide and 663 (13·4%) ... assigned to placebo (HR 0·88, 95% CI 0·79–0·99; p=0·026)
  • Cardiovascular death · Table 2
    Cardiovascular death† 317 (6·4%) 1·22 346 (7·0%) 1·34 0·91 (0·78–1·06) 0·21
  • All-cause death · Summary, Findings; Table 2
    All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067)
  • Myocardial infarction · Table 2
    Myocardial infarction 223 (4·5%) 0·87 231 (4·7%) 0·91 0·96 (0·79–1·15) 0·63
  • Stroke · Table 2
    Stroke 158 (3·2%) 0·61 205 (4·1%) 0·81 0·76 (0·62–0·94) 0·010
  • Hospitalisation for heart failure · Table 2
    Hospital admission for heart failure or urgent visit 213 (4·3%) 0·83 226 (4·6%) 0·89 0·93 (0·77–1·12) 0·46
  • Kidney composite · Table 2
    Renal outcome§ 848 (17·1%) 3·47 970 (19·6%) 4·07 0·85 (0·77–0·93) 0·0004
  • Retinopathy complications · Table 2: Primary and secondary outcomes (footnote ‡)
    Eye outcome‡ 95 (1·9%) 0·37 76 (1·5%) 0·30 1·24 (0·92–1·68) 0·16
  • Hospitalisation for unstable angina · Table 2: Primary and secondary outcomes
    Hospital admission for unstable angina 88 (1·8%) 0·34 77 (1·6%) 0·30 1·14 (0·84–1·54) 0·41

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
REWIND
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
CV outcomesPhase 3completed2011-07 → 2018-089901MACE HR 0.88 (0.79–0.99)NCT01394952

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Dulaglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/dulaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.